Trial Profile
A Multicenter, Phase I/II Trial of Anastrozole, Palbociclib, Trastuzumab and Pertuzumab in HR-positive, HER2-positive Metastatic Breast Cancer
Status:
Active, no longer recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 12 Feb 2024
Price :
$35
*
At a glance
- Drugs Anastrozole (Primary) ; Palbociclib (Primary) ; Pertuzumab (Primary) ; Trastuzumab (Primary)
- Indications Advanced breast cancer; HER2 positive breast cancer; Male breast cancer
- Focus Adverse reactions; Therapeutic Use
- Acronyms ASPIRE
- 05 Sep 2023 Planned End Date changed from 1 Jul 2023 to 1 Dec 2024.
- 05 Sep 2023 Planned primary completion date changed from 1 Jul 2023 to 1 Jul 2024.
- 05 Oct 2022 Planned primary completion date changed from 1 Jul 2022 to 1 Jul 2023.